Medical Device Manufacturer & Distributor
European Medical Device Manufacturer and US Distributor
On NextCompany since September 30, 2026 (15 days)
Location undisclosed
Business overview
The company manufactures cardiovascular and neuro-cognitive monitors in Europe and distributes them in the US. Independent physician-owned practices account for approximately 80% of revenue; hospitals and researchers also buy its products. Its devices carry FDA 510(k) clearance, and it holds over 2,000,000 unique patient datasets. The company introduced recurring software licensing fees in 2022.
Gross revenue reached $7,104,104, and EBITDA reached $4,204,061. The sole shareholder seeks a full exit and offers operational transition support. The business leases facilities totaling 9,400 square feet; affiliated real estate falls outside the sale.
Who is a good fit for this business
- Strategic acquirers in cardiovascular and neuro-cognitive monitoring can build on the company's manufacturing and US distribution.
- Buyers seeking recurring medical device software revenue can evaluate the licensing fees introduced in 2022.
- Buyers planning an owner transition can work with a shareholder willing to support operations after exit.
Details
- Reason for selling
- The sole shareholder is seeking a full exit and is willing to remain to support operations and ensure a smooth transition.
- Real estate
- Leased
Frequently Asked Questions
The company manufactures cardiovascular and neuro-cognitive monitoring instruments in Europe and distributes them in the US. Independent physician-owned practices account for approximately 80% of revenue. Hospitals and researchers also buy its products.
The business reports $7,104,104 in gross revenue and $4,204,061 in EBITDA. The company also collects recurring software licensing fees, which it introduced in 2022.
The business leases facilities totaling 9,400 square feet. Affiliated real estate falls outside the sale; the parties can negotiate a long-term lease.
The sole shareholder seeks a full exit. The shareholder remains willing to support operations during the transition.
The company identifies international sales, next-generation devices, AI capabilities, and GPO contracts as growth opportunities. It also holds over 2,000,000 unique patient datasets.